J-GLOBAL ID：200901017266702238
Update date: Mar. 07, 2024
Takahashi Masato
Takahashi Masato
Research field (4)：
Hematology and oncology
, Tumor biology
, Tumor diagnostics and therapeutics
, General surgery, pediatric surgery
Research keywords (3)：
腫瘍学
, 乳腺
, 外科
Research theme for competitive and other funds (1)：
乳癌の悪性度診断
Papers (148)：
Masato Takahashi, Tomofumi Osako, Hiroyuki Yasojima, Kenichi Inoue, Masahiro Kawashima, Hideki Maeda, Akemi Ichikawa, Yasuaki Muramatsu, Norikazu Masuda. Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole. Breast cancer (Tokyo, Japan). 2023
Hiroko Masuda, Yuko Tanabe, Hitomi Sakai, Koji Matsumoto, Akihiko Shimomura, Mihoko Doi, Yasuo Miyoshi, Masato Takahashi, Yasuaki Sagara, Shinya Tokunaga, et al. Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). Breast (Edinburgh, Scotland). 2023. 71. 22-28
Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). Journal for ImmunoTherapy of Cancer. 2023. 11. 9. e007126-e007126
Yumi Moriya, Tomohiro Oshino, Mitsuchika Hosoda, Karin Shikishima, Shun Miura, Jun Muto, Tatsuya Kato, Masato Takahashi. A Case of Pneumothorax Required Surgical Treatment as a Complication of Paclitaxel with Bevacizumab Treatment. Case Reports in Oncology. 2023. 16. 1. 797-802
Tsuguo Iwatani, Fumikata Hara, Tadahiko Shien, Masato Takahashi, Norikazu Masuda, Hiroyuki Yasojima, Yasuaki Sagara, Tomonori Mizutani, Keita Sasaki, Kenichi Nakamura, et al. Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A); preliminary study findings. CANCER RESEARCH. 2021. 81. 4
Yutaka Yamamoto, Hiroji Iwata, Taira Naruto, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, et al. A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. CANCER RESEARCH. 2021. 81. 4
Ozaki Yukinori, Mukohara Toru, Tsurutani Junji, Takahashi Masato, Matsumoto Koji, Futamura Manabu, Masuda Norikazu, Kitano Shigehisa, Yoshimura Kenichi, Minami Hironobu, et al. HER2陰性転移性乳癌患者に対する一次治療としてのニボルマブ+パクリタキセル+ベバシズマブ併用療法の有効性を評価する多施設第II相試験 WJOG9917B NEWBEAT試験(A multicenter Phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial). 日本乳癌学会総会プログラム抄録集. 2020. 28回. 32-32
